2-(Butan-2-yl)-5-methyl-1H-imidazole | 61893-07-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(Butan-2-yl)-5-methyl-1H-imidazole
• 英文别名: 2-butan-2-yl-5-methyl-1H-imidazole
• CAS: 61893-07-0
• 化学式: C₈H₁₄N₂
• 分子量: 138.21
• InChiKey: VOVQZEWZJXQFFI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• Triazine derivatives as inhibitors of phosphodiesterases
  申请人：Stange Hans

  公开号：US20100120762A1

  公开（公告）日：2010-05-13

  The invention relates to triazine derivatives of formula (I): which are inhibitors of phosphodiesterase 2 or 10, useful in treating central nervous system diseases such as psychosis and also in treating, for example, obesity, type 2 diabetes, metabolic syndrome, glucose intolerance, and pain.

  该发明涉及式（I）的三嗪衍生物，它们是磷酸二酯酶2或10的抑制剂，可用于治疗中枢神经系统疾病，如精神病，并且还可用于治疗例如肥胖症、2型糖尿病、代谢综合征、葡萄糖耐受不良和疼痛。
• MODULATORS OF THE INTEGRATED STRESS PATHWAY
  申请人：Calico Life Sciences LLC

  公开号：EP3778575A1

  公开（公告）日：2021-02-17

  Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.

  本文提供了用于调节综合应激反应（ISR）和治疗相关疾病、失调和病症的化合物、组合物和方法。
• INHIBITORS OF JUN N-TERMINAL KINASE
  申请人：IMAGO PHARMACEUTICALS, INC.

  公开号：US20200039972A1

  公开（公告）日：2020-02-06

  The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula: or a salt or solvate thereof, wherein ring A, C a , C b , Z, R 5 , W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.
• [EN] TRIAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES<br/>[FR] DÉRIVÉS DE TRIAZINE EN TANT QU'INHIBITEURS DE PHOSPHODIESTÉRASES
  申请人：STANGE HANS

  公开号：WO2010054253A1

  公开（公告）日：2010-05-14

  The invention relates to triazine derivatives of formula (I): which are inhibitors of phosphodiesterase 2 or 10, useful in treating central nervous system diseases such as psychosis and also in treating, for example, obesity, type 2 diabetes, metabolic syndrome, glucose intolerance, and pain.